Proactive Investors - Run By Investors For Investors

CytoDyn takes major step forward filing trial protocol for HIV Monotherapy

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to bring news the company has filed to the FDA,  the pivotal trial protocol for leronlimab as a monotherapy for HIV patients. 

Pourhassan also shared details about the work involved to get to this point and what the next stage is.

 
View full CYDY profile View Profile

CytoDyn Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use